Targeting Lung Cancer in Rare Disease Patient Populations

SOMERVILLE, MA— June 25, 2018 — Andarix Pharmaceuticals, a clinical stage
company aimed at developing a targeted peptide therapies for hard to treat cancers,
announced today that it will present a poster at the Metals in Medicine Gordon Research
.The conference will take place June 25-29 in Andover, NH.

The theme of the conference is: The Indispensable Role of Metals in Medical
Diagnostics, Therapeutics and Beyond. Andarix will be presenting clinical findings
pertaining to Tozaride, a Rhenium metal-based drug developed by the company. The
conference is an opportunity for Andarix to present its innovative technology to world
leading scientists and international metal-science experts.

About Tozaride
Tozaride is a novel, best-in-class therapeutic for lung and other cancers, which is based
on a radio-labeled somatostatin peptide. Early clinical studies demonstrated that
Tozaride is well tolerated and that treatment can promote disease stabilization and
improve overall survival in heavily pre-treated advanced lung cancer patients. Tozaride
targeted radiotherapy represents a new treatment paradigm which is expected to yield
significant clinical benefits for both small cell lung cancer (SCLC), and non-small cell
lung cancer (NSCLC) patients. This therapeutic stands to provide an additional
treatment option for patients who are not eligible for, or who have not responded to
current therapies.

About Andarix Pharmaceuticals
Andarix Pharmaceuticals is a clinical stage company aimed at developing targeted
imaging and therapeutics for lung, neuroendocrine, and other cancers based on a
proprietary somatostatin peptide conjugate. Extensive research has demonstrated that
somatostatin receptors are highly up-regulated in several solid tumors, and lung cancers
in particular, thus, supporting the efficacy of somatostatin conjugates as targeted
therapeutics for these cancers. Lung cancer is the second most common cancer in both
men and women in the US and is the leading cause of cancer mortality. In 2013, there
were an estimated 225,470 new diagnoses of non-small cell lung cancer (NSCLC) with
42,000 small cell lung cancer patients. To learn more about Andarix, please visit .

Andarix Pharmaceuticals